Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
778 USD | -0.03% | +1.00% | +33.46% |
07:00am | Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says | RE |
Mar. 28 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 41.32B | Sales 2025 * | 51.34B | Capitalization | 701B |
---|---|---|---|---|---|
Net income 2024 * | 10.89B | Net income 2025 * | 15.74B | EV / Sales 2024 * | 17.3 x |
Net Debt 2024 * | 14.38B | Net Debt 2025 * | 7.93B | EV / Sales 2025 * | 13.8 x |
P/E ratio 2024 * |
64.2
x | P/E ratio 2025 * |
43.6
x | Employees | 43,000 |
Yield 2024 * |
0.67% | Yield 2025 * |
0.77% | Free-Float | 99.79% |
Latest transcript on Eli Lilly and Company
1 day | -0.03% | ||
1 week | +1.00% | ||
Current month | +3.22% | ||
1 month | +2.68% | ||
3 months | +33.93% | ||
6 months | +42.89% | ||
Current year | +33.46% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 59 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 18 M€ | +6.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 778 | -0.03% | 3,209,424 |
24-03-27 | 778.2 | +0.42% | 2,297,713 |
24-03-26 | 774.9 | +0.23% | 2,099,042 |
24-03-25 | 773.1 | +0.33% | 1,806,584 |
24-03-22 | 770.6 | +0.05% | 1,981,019 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |